百利天恒子公司SystImmune与百时美施贵宝的合作触发2.5亿美元里程碑付款

Core Viewpoint - SystImmune, a wholly-owned subsidiary of Baillie Gifford (688506.SH), has entered into an exclusive licensing and collaboration agreement with Bristol-Myers Squibb (BMS) for the drug iza-bren (BL-B01D1, EGFR×HER3 dual antibody ADC), receiving an upfront payment of $800 million [1] Group 1 - The collaboration agreement includes a milestone payment of $250 million triggered by the completion of the global Phase II/III pivotal clinical trial IZABRIGHT-Breast01 [1] - SystImmune is eligible for additional near-term milestone payments of up to $250 million and potential further payments of up to $7.1 billion upon achieving specific development, registration, and sales milestones [1] - The milestone payments are contingent upon certain conditions, and the final amounts remain uncertain [1]